Abstract
The labeling of biomolecule using 99mTc-tricarbonyl is an interesting tool for the diagnosis of diseases. This labeling startegy has several advantages as compared to other common radiolabeling techniques. This review is a complete overview of synthesis and chemistry of 99mTc-tricarbonyl molecule for labeling peptides and proteins. Also, the effect of ligand type on the stability and in vivo biodistribution of 99mTc-tricarbonyl labeled biomolecules are discussed. Chemistries of cyclopentadienyl and hexa histidine tag as two important bifunctional chelating agents (BFCA) are presented. The in vitro and in vivo behaviors of some 99mTc-tricarbonyl labeled peptides and proteins are explained. Preclinical outcomes revealed that these labeled compounds are biologically, kinetically and thermodynamically stable. Findings showed that 99mTc-tricarbonyl labeled biomolecules are promising tools for future clinical applications in image diagnosis.
Keywords: Tricarbonyl, 99mTc, peptide, labeling.
Current Pharmaceutical Design
Title:The Past, Current Studies and Future of Organometallic 99mTc(CO)3 Labeled Peptides and Proteins
Volume: 22 Issue: 31
Author(s): Majid Piramoon and Seyed Jalal Hosseinimehr
Affiliation:
Keywords: Tricarbonyl, 99mTc, peptide, labeling.
Abstract: The labeling of biomolecule using 99mTc-tricarbonyl is an interesting tool for the diagnosis of diseases. This labeling startegy has several advantages as compared to other common radiolabeling techniques. This review is a complete overview of synthesis and chemistry of 99mTc-tricarbonyl molecule for labeling peptides and proteins. Also, the effect of ligand type on the stability and in vivo biodistribution of 99mTc-tricarbonyl labeled biomolecules are discussed. Chemistries of cyclopentadienyl and hexa histidine tag as two important bifunctional chelating agents (BFCA) are presented. The in vitro and in vivo behaviors of some 99mTc-tricarbonyl labeled peptides and proteins are explained. Preclinical outcomes revealed that these labeled compounds are biologically, kinetically and thermodynamically stable. Findings showed that 99mTc-tricarbonyl labeled biomolecules are promising tools for future clinical applications in image diagnosis.
Export Options
About this article
Cite this article as:
Piramoon Majid and Hosseinimehr Jalal Seyed, The Past, Current Studies and Future of Organometallic 99mTc(CO)3 Labeled Peptides and Proteins, Current Pharmaceutical Design 2016; 22 (31) . https://dx.doi.org/10.2174/1381612822666160623081838
DOI https://dx.doi.org/10.2174/1381612822666160623081838 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Current Pharmaceutical Biotechnology Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery Has Bevacizumab (Avastin) Given Extra Therapeutic Gain in Metastatic Colorectal Cancer and Malignant Brain Gliomas? Systematic Review Answering this Question
Recent Patents on Inflammation & Allergy Drug Discovery Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets 2,5-Diketopiperazines (DKPs): Promising Scaffolds for Anticancer Agents
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine <i>Lophira alata</i> Suppresses Phorbol Ester-Mediated Increase in Cell Growth via Inhibition of Protein Kinase C-α/Akt in Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry